The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1351
November 15, 2010
View Complete Issue         Table of Contents 2019 
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
November 15, 2010 (Issue: 1351)
The FDA has approved incobotulinumtoxinA (Xeomin – Merz) for treatment of cervical dystonia and blepharospasm in adults. It has been commercially available in Germany since 2005. Several formulations of botulinum toxin type A (Botox; Dysport)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Botulinum Toxin (Xeomin) for Cervical Dystonia and Blepharospasm
Article code: 1351b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.